Navigation Links
Stereotaxis Reports Third Quarter Financial Results
Date:11/7/2011

reported for the third quarter 2010.  The weighted average shares outstanding for the third quarter of 2011 totaled 54.9 million, compared with 50.1 million in the third quarter of 2010.  The increase in shares outstanding was due in large part to the issuance of 4.6 million shares as part of the stock offering completed in November 2010.

At September 30, 2011, Stereotaxis had cash and cash equivalents of $17.0 million, compared to $23.3 million on June 30, 2011.  Total debt was $29.0 million, including $16.9 million drawn against the Company's $20 million line of credit.  Cash burn for the third quarter 2011 was $6.4 million.

Rebalancing Operating Expenses Around the Epoch and Odyssey PlatformsIn order to ensure the successful commercialization of the Epoch and Odyssey platforms, as well as conserve resources, Stereotaxis began implementing a wide ranging plan in the 2011 third quarter that includes rebalancing and reducing operating expenses to minimize the Company's cash burn, while continuing to fund R&D investment in key growth areas.  As of September 30, 2011, the Company has completed the majority of the operating expense reductions through headcount and discretionary spending cuts and continues to implement processes and changes to further reduce operating costs.  The Company anticipates that this will result in an operating expense reduction of 15% to 20% on a year-to-date September 30th annual run rate basis.

Non-Equity Capital RaiseOn October 11, 2011, Company entered into a non-binding term sheet with an institutional investor to raise non-equity capital.  The Company expects the capital raise to be completed by November 30, 2011, satisfying the Company's obligation under the Fourth Loan Modification Agreement with Silicon Valley Bank.  The Company and the institutional investor are working diligently and in good faith to close the transaction, subject to customary closing con
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
2. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
3. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
4. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
5. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
7. Stereotaxis to Report Second Quarter 2011 Financial Results and Conduct Conference Call on August 8, 2011
8. Stereotaxis and Biosense Webster Announce New Strategic Collaboration
9. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
10. Stereotaxis Reports First Quarter 2011 Financial Results
11. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Pacific Medical ... its new website design . The main website, ... that showcases the company,s new services and content relevant ... implementing a new streamlined design, viewers can now better ... for health care practices and create a more visible ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2
... Research and Manufacturers of America (PhRMA) today announced the ... Directors. "We are pleased to welcome four ... said PhRMA President and Chief Executive Officer John J. ... sectors in the U.S., they bring to the table ...
... Dec. 21, 2010 Reportlinker.com announces that a ... catalogue: Thai Self-monitoring of Blood ... http://www.reportlinker.com/p0350305/Thai-Self-monitoring-of-Blood-Glucose-SMBG-Devices-and-Strips-Market.html This Market ... the dynamics of blood glucose monitoring device sales ...
Cached Medicine Technology:PhRMA Elects Four New Members to Board of Directors 2PhRMA Elects Four New Members to Board of Directors 3
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... When a prominent bank reveals a successful cyber attack, ... 27th, when news began surfacing about the FBI probing ... and at least one other bank. But when news gets ... seven prominent banks , everyone starts thinking about their own ... quickly goes viral. Bloomberg followed up on Friday with ...
(Date:8/30/2014)... Columbus, Ohio (PRWEB) August 30, 2014 As ... serioius birth defect when give to pregnant mothers, Wright & ... District Judge Cynthia M. Rufe. The remand in ... are representative of 18 states and are involved in one ... allows them to have their Zoloft birth defect lawsuit sent ...
(Date:8/30/2014)... Barton Associates, an industry leading physician, ... , announces a new office location in Keene, NH, ... headquartered in Peabody, MA, with additional staffing centers in ... Jupiter, FL. , Barton Associates made the decision to ... crisis affecting the United States, a crisis that will ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary recommendations ... acute coronary syndromes (ACS) are published today in ... was written jointly by the European Heart Rhythm ... and the European Association of Percutaneous Cardiovascular Interventions ... Bulent Gorenek (Turkey), chairperson of the task force, ...
Breaking Medicine News(10 mins):Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2
... procedure cuts conception rate, study found , THURSDAY, Oct. ... 15 minutes after being artificially inseminated greatly boost their ... women treated for subfertility with IUI [intrauterine insemination] to ... higher chance at conceiving," said Inge Custers, lead author ...
... In ... announced the launch of its online floral gift program, celebrating caregivers who love and ... with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In recognition of November,s Alzheimer,s Awareness Month, ...
... thrown off schedule by Daylight Saving Time , FRIDAY, ... you,ll get in most parts of the country over the ... Time could spell trouble for your body clock, a sleep ... the sleep disorders research program in the division of sleep ...
... led to bigger, healthier infants, studies show , FRIDAY, ... the list of people who should get H1N1 swine ... highlight the benefits of vaccination for moms-to-be and their ... reduced rates of hospitalization top the findings, which are ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that net ... $0.43 per diluted share, versus $37.9 million, or $0.71 per diluted ... are in line with the preliminary earnings range that the Company ... elevated medical costs associated with the onset of what appears to ...
... AcelRx Pharmaceuticals, Inc. today announced that it ... the FDA for ARX-01, a drug/device combination product ... which enables delivery of sufentanil by the non-invasive ... alternative to intravenous patient-controlled analgesia (IV PCA) for ...
Cached Medicine News:Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 2Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 3
... contains primers and a FAM-labeled probe that ... gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an ... Red reporter dyes such as the Cepheid ...
...
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: